Zanubrutinib plus salvage chemotherapy for relapsed or refractory diffuse large B-cell lymphoma

INTRODUCTION: Relapsed or refractory diffuse large B-cell lymphoma (R/R DLBCL) has poor clinical outcomes when treated with conventional salvage chemotherapy. Monotherapy using zanubrutinib, a selective Bruton’s tyrosine kinase (BTK) inhibitor, has achieved modest antitumor effect in R/R DLBCL. Here...

Descripción completa

Detalles Bibliográficos
Autores principales: Yuan, Xianggui, Li, Xian, Huang, Yurong, Jin, Xueli, Liu, Hui, Zhao, Aiqi, Zhang, Weiping, Qian, Wenbin, Liang, Yun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Immunology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9729240/
https://www.ncbi.nlm.nih.gov/pubmed/36505470
http://dx.doi.org/10.3389/fimmu.2022.1015081

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9729240/
https://www.ncbi.nlm.nih.gov/pubmed/36505470
http://dx.doi.org/10.3389/fimmu.2022.1015081

Ejemplares similares